Antiplatelet Effects of PCSK9 Inhibitors in Primary Hypercholesterolemia

Antiplatelet Effects of PCSK9 Inhibitors in Primary Hypercholesterolemia

Proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors are a novel group of hypolipidemic drugs that are recommended particularly for high-risk hypercholesterolemia patients, including those with primary hypercholesterolemia (PH), where lifelong exposure to high low-density lipoprotein (LD...

Full description

Bibliographic Details
Main Authors: Piotr Pęczek, Mateusz Leśniewski, Tomasz Mazurek, Lukasz Szarpak, Krzysztof J. Filipiak, Aleksandra Gąsecka
Format: Article
Language:English
Published: MDPI AG 2021-05-01
Series:Life
Subjects:
PCSK9 inhibitors
platelets
primary hypercholesterolemia
LDL-cholesterol
atherosclerosis
treatment
Online Access:https://www.mdpi.com/2075-1729/11/6/466

Internet

https://www.mdpi.com/2075-1729/11/6/466

Similar Items